Avalo Therapeutics Inc (NASDAQ: AVTX): Why Investors Shouldn’t Ditch AVTX Stock In 2023

In the last trading session, 11.05 million Avalo Therapeutics Inc (NASDAQ:AVTX) shares changed hands as the company’s beta touched 1.15. With the company’s per share price at $0.09 changed hands at $0.0 or -2.17% during last session, the market valuation stood at $17.31M. AVTX’s last price was a discount, traded about -6666.67% off its 52-week high of $6.09. The share price had its 52-week low at $0.08, which suggests the last value was 11.11% up since then. When we look at Avalo Therapeutics Inc’s average trading volume, we note the 10-day average is 23.02 million shares, with the 3-month average coming to 74.93 million.

Analysts gave the Avalo Therapeutics Inc (AVTX) stock a consensus recommendation rating of a Hold, calculated at a mean rating of 3.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended AVTX as a Hold, 0 felt it is a Buy and 0 rated the stock as Underweight. Avalo Therapeutics Inc’s EPS for the current quarter is expected to be -$0.02.

Top 5 Artificial Intelligence Stocks to Buy for 2024

By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it. According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."

Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"


Avalo Therapeutics Inc (NASDAQ:AVTX) trade information

Instantly AVTX was in red as seen at the end of in last trading. With action -0.44%, the performance over the past five days has been red. The drop to weekly highs of 0.1064 on Friday, 11/17/23 subtracted -2.17% to the stock’s daily price. The company’s shares are showing year-to-date downside of -98.21%, with the 5-day performance at -0.44% in the red. However, in the 30-day time frame, Avalo Therapeutics Inc (NASDAQ:AVTX) is -28.34% down. Looking at the short shares, we see there were 12.88 million shares sold at short interest cover period of 0.2 days.

The consensus price target for the stock as assigned by Wall Street analysts is $0.75, meaning bulls need an upside of 88.0% from its current market value. According to analyst projections, AVTX’s forecast low is $0.75 with $0.75 as the target high. To hit the forecast high, the stock’s price needs a -733.33% plunge from its current level, while the stock would need to soar -733.33% for it to hit the projected low.

Avalo Therapeutics Inc (AVTX) estimates and forecasts

Data shows that the Avalo Therapeutics Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -97.35% over the past 6 months, a 90.97% in annual growth rate that is considerably higher than the industry average of 11.30%. Moreover, analysts have looked to higher expectations by upgrading its fiscal year 2023 revenue estimates. The rating firms predict current quarter revenue for Avalo Therapeutics Inc will rise 98.10%, while the growth in revenue is estimated to hit 97.60% for the next quarter. Year-over-year growth is forecast to reach -90.60% down from the last financial year.

Consensus estimates given by 1 financial analysts project the company’s revenue in the current quarter to hit an average of $300k. 1 analysts are of the opinion that Avalo Therapeutics Inc’s revenue for the quarter ending Mar 2024 will be $300k. The company’s revenue for the corresponding quarters a year ago was $896k and $475k respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -66.50%. The estimates for the next quarter sales put growth at -36.80%.

The 2023 estimates are for Avalo Therapeutics Inc earnings to increase by 90.97%.

AVTX Dividends

Avalo Therapeutics Inc is expected to release its next quarterly earnings report on November 09.

Avalo Therapeutics Inc (NASDAQ:AVTX)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 1.86% of Avalo Therapeutics Inc shares while 35.76% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 36.44%. There are 35.76% institutions holding the Avalo Therapeutics Inc stock share, with VR Adviser, LLC the top institutional holder. As of Jun 29, 2023, the company held 6.17% of the shares, roughly 1.25 million AVTX shares worth $0.44 million.

Nantahala Capital Management, LLC holds the second largest percentage of outstanding shares, with 2.75% or 0.56 million shares worth $0.2 million as of Jun 29, 2023.

Among Mutual Funds, the top two as of Jun 29, 2023 were Vanguard Total Stock Market Index Fund and iShares Micro Cap ETF. With 0.12 million shares estimated at $42560.0 under it, the former controlled 0.59% of total outstanding shares. On the other hand, iShares Micro Cap ETF held about 0.37% of the shares, roughly 75094.0 shares worth around $7509.0.

On Key

Related Posts